Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
The competitive bidding process for Medivation shows just how much big pharma is willing to pay for commercial-stage oncology assets. Now that Pfizer has won the biotech, it will have to prove Xtandi is worth the price.
You may also be interested in...
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.